John Parkinson

The investigational therapy developed by Entasis is indicated for treatment of Acinetobacter baumannii.

In the latest Morbidity and Mortality Weekly Report, authors offer some strategies to avoid SARS-CoV-2 infection in this patient population as well as the US government changes course on COVID-19 vaccine policy.

The federal agency does not want clinicians utilizing this neutralizing antibody as newer, circulating COVID-19 strains and efficacy against them is limited.

In the CDC’s latest Morbidity and Mortality Weekly Report, investigators reported the Moderna and Pfizer-BioNTech updated vaccines helped prevent acute infection from the latest Omicron mutations.

The new guidance looks at preexposure and postexposure prophylaxis as well as treatment for COVID-19.

A new study demonstrated continuous neutralization after 3 doses.

In this week’s meeting, FDA is expected to ask their advisory committee to consider changes to simplify the vaccination schedule and look at delivering it annually, much like an influenza vaccine.

A Chinese epidemiologist made this claim this weekend as the country gathers for its Lunar New Year celebrations.

A mathematical modeling study for HPTN 083 demonstrated both forms of PrEP vs not taking anything remained efficacious in preventing infection.

Although vaccine rates overall remain high, a new report shows a reduction 2 years in a row, leaving thousands of children not vaccinated against vaccine-preventable viruses.

A retrospective study showed that exercise was found to have a protective association to adverse COVID-19 outcomes.

Based on the Data and Safety Monitoring Board DSMB’s recommendation, the study will be discontinued.

With limited health care infrastructure and large swaths of remote areas, developing countries face difficulties in medical management with these viruses and parasitic diseases.

This act designed to allow pharmacists and technicians the ability to administer certain vaccines without a prescriber order will lapse next year. A new report looks at vaccination trends in the US and how pharmacists are playing a vital role in administering vaccines.

With these results, the company plans to submit their investigational vaccine, MRNA-1345, for regulatory approval in the first half of 2023.

This live-attenuated investigational vaccine was developed by Codagenix, which uses its codon de-optimization platform for its candidates.

A CDC report looked at 2 vaccine safety surveillance systems for the bivalent boosters in this population and there were no reports of myocarditis or death. Many of the reports were due to vaccine errors and not adverse events.

The two agencies said one of the vaccine surveillance systems prompted an investigation into whether there was a safety concern for ischemic stroke in seniors for this booster.

A randomized trial found the antidepressant to be ineffectual in helping improve time to sustained recovery.

A 2-year retrospective study looking at patients admitted to the ICU showed that the number of intubated males infected with Acinetobacter baumannii (AB) was double the number of intubated females.

Recent numbers show a lack of new people entering the field combined with existing shortfalls in many US locations.These factors demonstrate a potentially dangerous reduction in this vital medical specialty.

Clostridioides difficile (CDI) and recurrence can create a tremendous burden on patients’ quality of life as well as become a financial burden to individual healthcare systems thus creating downstream costs for individual hospitals.

The agency licensed the new indication for Sanofi’s Adacel (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed [Tdap]) shot for immunization during the third trimester of pregnancy.

Research will focus on new technologies for early diagnosis of severe illnesses resulting from SARS-CoV-2 infection.

The company is moving forward with vaccines to address respiratory and latent viruses as well as oncology.

The investigational antiviral showed the potential of another therapy that could benefit this patient population that is at risk for hospitalization and death.

Newer diagnostic technologies can play a role in identifying specific bacterium, decrease the time to optimal therapy, and offer the possibility of better outcomes.

Central Ohio has seen 82 pediatric cases since November, and more than a third of children infected have been hospitalized.

Developed by Sanofi and AstraZeneca, the single-dose long-acting antibody was designed to help protect all infants from birth through their first respiratory syncytial virus (RSV) season.

A new Infectious Diseases Society of America (IDSA) board member and vice president offers some insights on the leadership’s goals and direction for 2023.